Brookstone Capital Management Purchases Shares of 29,373 Elanco Animal Health Incorporated $ELAN

Brookstone Capital Management purchased a new position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) in the fourth quarter, according to its most recent filing with the SEC. The firm purchased 29,373 shares of the company’s stock, valued at approximately $665,000.

Several other hedge funds have also recently made changes to their positions in the business. SJS Investment Consulting Inc. lifted its stake in shares of Elanco Animal Health by 2,563.5% in the 3rd quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company’s stock valued at $28,000 after purchasing an additional 1,333 shares during the period. Huntington National Bank boosted its position in shares of Elanco Animal Health by 136.7% during the 3rd quarter. Huntington National Bank now owns 1,882 shares of the company’s stock valued at $38,000 after purchasing an additional 1,087 shares in the last quarter. Whittier Trust Co. of Nevada Inc. grew its stake in Elanco Animal Health by 80.3% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock worth $42,000 after purchasing an additional 900 shares during the period. Farther Finance Advisors LLC grew its stake in Elanco Animal Health by 79.3% during the third quarter. Farther Finance Advisors LLC now owns 2,151 shares of the company’s stock worth $43,000 after purchasing an additional 951 shares during the period. Finally, Fifth Third Bancorp increased its holdings in Elanco Animal Health by 3,018.3% in the third quarter. Fifth Third Bancorp now owns 2,900 shares of the company’s stock worth $58,000 after purchasing an additional 2,807 shares in the last quarter. 97.48% of the stock is owned by institutional investors.

Elanco Animal Health Stock Performance

Shares of Elanco Animal Health stock opened at $23.11 on Monday. Elanco Animal Health Incorporated has a one year low of $8.02 and a one year high of $27.72. The firm has a market capitalization of $11.49 billion, a price-to-earnings ratio of -48.14, a PEG ratio of 2.94 and a beta of 1.88. The business has a 50-day simple moving average of $24.56 and a 200 day simple moving average of $22.85. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.17 and a quick ratio of 1.08.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Tuesday, February 24th. The company reported $0.13 earnings per share for the quarter, topping analysts’ consensus estimates of $0.11 by $0.02. Elanco Animal Health had a positive return on equity of 7.16% and a negative net margin of 4.92%.The business had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.09 billion. During the same period in the prior year, the business earned $0.14 EPS. The firm’s revenue for the quarter was up 12.2% on a year-over-year basis. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. On average, research analysts anticipate that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on ELAN. Leerink Partners boosted their price target on Elanco Animal Health from $26.00 to $30.00 and gave the company an “outperform” rating in a research note on Tuesday, February 24th. KeyCorp raised their price objective on shares of Elanco Animal Health from $27.00 to $29.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Piper Sandler upgraded shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $24.00 to $30.00 in a research note on Thursday, January 22nd. JPMorgan Chase & Co. boosted their target price on shares of Elanco Animal Health from $24.00 to $28.00 and gave the company an “overweight” rating in a research report on Thursday, February 19th. Finally, UBS Group reissued a “buy” rating on shares of Elanco Animal Health in a research note on Tuesday, March 10th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $27.67.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.